Advertisement

Topics

Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal

10:39 EST 8 Jan 2018 | Speciality Pharma Journal

GHENT, Belgium, 8 January 2018 – Ablynx NV (Euronext Brussels and Nasdaq: ABLX) (“Ablynx” or the “Company”) today confirmed that on December 22, 2017 it received an unsolicited conditional proposal from Novo Nordisk A/S (CSE: NOVO B) (NYSE:NVO) (“Novo Nordisk”) to acquire all of the outstanding shares of Ablynx for €28.00 (or approximately $33.661) per …

Original Article: Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal

NEXT ARTICLE

More From BioPortfolio on "Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...